Stuart Therapeutics, Inc., a Stuart, Fla.-based clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, raised $11m in Series A funding.
The round was led by InFocus Capital Partners, with participation from the Wisconsin Alumni Research Foundation (WARF), MiMo Capital and BioBrit.
The proceeds from the round will fund Phase 2 clinical trials for the company’s proprietary reparative therapeutic candidate, ST-100.
Led by Eric Schlumpf, President & CEO, Stuart Therapeutics is a clinical-stage biopharmaceutical company conducting research and development of unique synthesized peptides as potential therapeutics for ophthalmic diseases.
ST-100, which will be tested as a topical drop formulation for the treatment of dry eye disease, is the first drug candidate from Stuart’s platform technology, PolyCol™. The company is also pursuing variants of the platform for a variety of additional ophthalmic indications, such as glaucoma, dry and wet age-related macular degeneration, and neurotrophic keratitis. PolyCol is a synthesized peptide, specifically designed to repair and restore the structural integrity of, and cell interaction domains in, extracellular matrix (ECM) collagen. ECM collagen is damaged in a number of chronic inflammatory diseases, including dry eye disease.